INOLYSIS Selected for Lightning Oral Presentation at ECM2026 We are excited to share that we have been selected for a lightning oral presentation at the Extracellular Matrix Pharmacology Congress (ECM2026) , taking place June 14–17, 2026, in Copenhagen, Denmark. ECM2026 is a leading international congress that brings together academic, clinical, and industry experts to explore the latest advances in extracellular matrix biology and translational medicine. This selection reflects the...

INOLYSIS Selected for StartSmart SEE Accelerator 2026 We’re happy to announce that INOLYSIS is joining the StartSmart SEE Accelerator , following a competitive selection process (30 teams selected from more than 100 applicants). The 3-month intensive programme designed to support early-stage ventures through expert mentoring, structured workshops, and application of the MIT Disciplined Entrepreneurship framework. Over the coming months, we’ll work closely with experienced mentors, strategic...

INOLYSIS at the 9th Systemic Sclerosis World Congress The 9th Systemic Sclerosis World Congress , organized by the World Scleroderma Foundation, brings together leading experts to advance research in systemic sclerosis (SSc)—a severe, multi-organ fibrotic disease driven by persistent fibroblast activation and associated with high unmet medical need. At this year’s meeting, our Founder, George Kollias, delivered a keynote on “Fibroblasts in Inflammation and Fibrosis.” His presentation...